U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07230977) titled 'GenSci139 in Patients With Advanced Solid Tumors' on Sept. 22.
Brief Summary: This is a phase I, two-part, multicenter, first-in-human study. The Part 1 study will assess the safety, tolerability, preliminary anti-tumor activities, PK profile, immunogenicity and biomarker of GenSci139 in participants with locally advanced or metastatic solid tumors, as well as identity MTD (if any) and RDE. The Part 2 study is to further evaluate the preliminary anti-tumor activities, safety, PK profile, immunogenicity and biomarker of GenSci139 at RDE dose levels with selected advanced cancers.
Study Start Date: Dec. 21
Study Type: INTERVENTIONAL...